RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
648. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of
blood pressure control on diabetic microvascular complications
in patients with hypertension and type 2 diabetes.
Diabetes Care 23 (suppl 2): B54-B64, 2000.
649. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC,
Raij L: Converting enzyme inhibition in chronic renal failure.
Am J Kidney Dis 13: 120-126, 1989.
650. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M,
Stallone C, y cols. Long-term comparison between captopril
and nifedipine in the progression of renal insufficiency.
Kidney Int 42: 452-458, 1992.
651. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the
Collaborative Study Group: The effect of angiotensin-converting-enzyme
inhibition on diabetic nephropathy. N Engl J
Med 329: 1456-1462, 1993.
652. Hannedouche T, Landais P, Goldfarb B, Esper NE, Fournier A,
Godin M, y cols. : Randomised controlled trial of enalapril
and b blockers in non-diabetic chronic renal failure. BMJ
309: 833-837, 1994.
653. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith
PS, Becker GJ: Angiotensin-converting enzyme inhibition in
nondiabetic progressive renal insufficiency: a controlled
double-blind trial. Am J Kidney Dis 27: 489-495, 1996.
654. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE,
Montolese M, y cols. and the Angiotensin-converting-enzyme
Inhibition in Progressive Renal Insufficiency study group:
Effect of the angiotensin-converting-enzyme inhibitor benazepril
on the progression of renal insufficiency. N Engl J Med
334: 939-945, 1996.
655. The GISEN group (Gruppo Italiano di Studi Epidemiologici
in Nefrologia): Randomised placebo-controlled trial of effect
of ramipril on decline in glomerular filtration rate and risk of
terminal renal failure in proteinuric, non-diabetic nephropathy.
Lancet 349: 1857-1863, 1997.
656. Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Díez J,
on behalf of the investigators of the ESPIRAL study: A random
comparison of fosinopril and nifedipine GITS in
patients with primary renal disease. J Hypertension 19:
1871-1876, 2001.
657. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-
Enzyme Inhibition and Progressive Renal Disease Study
Group: Effect of angiotensin-converting-enzyme inhibitors
on the progression of nondiabetic renal disease: a metaanalysis
of randomized trials. Ann Intern Med 127: 337-345,
1997.
658. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de
Jong PE, de Zeeuw D, y cols. for the AIPRD Study Group:
Progression of chronic kidney disease: the role of blood
pressure control, proteinuria, and angiotensin-converting
enzyme inhibition. Ann Intern Med 139: 244-252, 2003.
659. Viberti G, Wheeldon NM; for the MicroAlbuminuria
Reduction with VALsartan (MARVAL) Study Investigators:
Microalbuminuria reduction with valsartan in patients with
type 2 diabetes mellitus. A blood pressure-independent
effect. Circulation 106: 672-678, 2002.
660. Praga M, Fernández-Andrade C, Luño J, Arias M, Poveda R,
Mora J, y cols. Antiproteinuric efficacy of losartan in comparison
with amlodipine in nondiabetic proteinuric renal disease:
a double-blind, randomized clinical trial. Nephrol Dial
Transplant 18: 1806-1813, 2003.
661. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T,
Ideura T: Combination treatment of angiotensin-II receptor
blocker and angiotensin-converting-enzyme inhibitor in
non-diabetic renal disease (COOPERATE): a randomized
controlled trial. Lancet 361: 117-124, 2003.
662. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG,
Rouleau JL, y cols. for the Collaborative Study Group:
Cardiovascular outcomes in the Irbesartan Diabetic
Nephropathy Trial of patients with type 2 diabetes and overt
nephropathy. Ann Intern Med 138: 542-549, 2003.
663. American Diabetes Association: Position statement.
Nephropathy in diabetes. Diabetes Care 27 (suppl 1): S79-
S82, 2004.
664. American Diabetes Association: Position statement.
Hypertension management in adults with diabetes. Diabetes
Care 27 (suppl 1): S65-S67, 2004.
665. Hemmelgarn BR, Zarnke KB, Campbell N, Feldman RD,
McKay DW, McAlister FA, y cols. for the Canadian
Hypertension Education Program: The 2004 Canadian
recommendations for the management of hypertension: Part
I - Blood pressure measurement, diagnosis and assessment of
risk. Can J Cardiol 20: 31-40, 2004.
666. Khan NA, McAlister FA, Campbell NRC, Feldman RD,
Rabkin S, Mahon J, y cols. for the Canadian Hypertension
Education Program: The 2004 Canadian recommendations
for the management of hypertension: Part II - Therapy. Can J
Cardiol 20: 41-54, 2004.
667. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT,
Potter JF, y cols. British Hypertension Society guidelines.
Guidelines for management of hypertension: report of the
fourth working party of the British Hypertension Society,
2004-BHS IV. J Hum Hypertension 18: 139-185, 2004.
668. Palmer BF. Managing hyperkalemia caused by inhibitors of
the renin-angiotensin-aldosterone system. N Engl J Med 351:
585-592, 2004.
669. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated
elevations in serum creatinine. Is this a cause
for concern? Arch Intern Med 160: 685-693, 2000.
670. Vogt L, Navis G, de Zeeuw D. Renoprotection: A matter of
blood pressure reduction or agent-characteristics? J Am Soc
Nephrol 13: S202-S207; 2002.
671. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA,
Broadstone V, y cols. Renal protective effect of enalapril in
hypertensive NIDDM: Role of baseline albuminuria. Kidney
Int 45 (Suppl): S150-S155; 1994.
672. Laffel LMB, McGill J, Gans D. The beneficial effects of angiotensin-converting
enzyme inhibition with captopril on diabetic
nephropathy in normotensive IDDM patients with
microalbuminuria. Am J Med 99: 497-503; 1995.
673. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective
effect of angiotensin-converting enzyme inhibition
in non-insulin dependent diabetes mellitus: A 7-year
follow-up study. Arch Intern Med 156: 286-289; 1996.
674. Praga M, Hernandez E, Montoyo c, Andres A, Ruilope LM,
Rodicio JL. Long-term beneficial effects of angiotensin-converting
enzyme inhibition in patients with nephrotic proteinuria.
Am J Kidney Dis 20: 240-248; 1992.
675. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.
Chronic proteinuric nephropathies: Outcomes and response
to treatment in a prospective cohort of 352 patients with different
patterns of renal injury. Am J Kidney Dis 35: 1155-
1165; 2000.
676. Himmelmann A, Hansson L, Hansson BG, Hedstrand H,
Skogstrom K, Ohvrik J, y cols. ACE inhibition preserves renal
207